Dr. Ryan Morin receives Canadian Cancer Society Bernard and Francine Dorval Prize

Dr. Ryan Morin (Centre for Lymphoid Cancer) is the co-recipient of the Canadian Cancer Society (CCS) Bernard and Francine Dorval Prize. 

Dr. Morin is a national and international leader in his field of studying how changes to our genes lead to cancer. He has conducted cutting-edge research that has directly helped doctors understand, diagnose and better treat lymphomas. 

Study reveals cause for different outcomes for patients that experience early and late relapse of diffuse large B-cell lymphoma

A recent study conducted by TFRI-funded researchers at BC Cancer sheds light on the cause behind the different outcomes of patients with diffuse large B cell lymphoma (DLBCL) who experienced a relapse in their disease. The study confirmed that patients whose cancer relapses shortly after treatment typically have poor responses to additional chemotherapy-based treatment. However, when the relapse occurs more than two years from the time of diagnosis, the outcomes to chemotherapy are significantly better.

Research reveals insights into lymphoma relapse and treatment response

A recent study conducted by researchers at BC Cancer has shed light on the cause behind the different outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who experience a relapse of their disease. The study, led by Dr. Laura Hilton, staff scientist at BC Cancer’s Centre for Lymphoid Cancer (CLC), and Dr. David Scott, clinical director of the CLC, aimed to understand the molecular characteristics of the initial diagnostic and relapse tumour samples of patients with DLBCL.

Back to top